Latest Biotech News

The FDA twice declined to approve Replimune Group’s RP1, an oncolytic immunotherapy for melanoma previously granted breakthrough therapy status, raising fresh concerns for developers relying on...

UCB moved to expand its autoimmune pipeline by backing Ken Song’s T cell engager ambitions with a reported $2 billion bet on Candid, a company advancing T cell engager programs designed for...

Erasca’s shares sank 53% amid disclosure around a death connected to ERAS-0015’s treatment-related adverse event timeline in earlier data. The precision oncology company developing an oral pan-RAS...

Researchers used AI-guided design to partially eliminate isoleucine from proteins in an engineered Escherichia coli system by proposing structurally similar replacements across dozens of bacterial...

A study identifying CD44+ monocytes as drivers of inflammation in very premature infants advances mechanistic understanding of bronchopulmonary dysplasia (BPD), according to the report. The...

Work on bridging biomarker gaps for very low birth weight (VLBW) sepsis tests highlights ongoing unmet needs in neonatal diagnostics. Sepsis remains a leading cause of morbidity and mortality in...

A Nature Communications multicohort analysis links small-for-gestational-age constraints to long-term pulmonary impairments via axon guidance pathways. Investigators say the study provides “first...

A Karolinska Institutet-led study reported that low-dose endoxifen, an active metabolite of tamoxifen, can significantly reduce mammographic breast density with fewer side effects, with results...

UCB has committed $2 billion toward expanding Candid’s T-cell engager platform, signaling a major push into engineered cell-engaging therapies for autoimmune disease. The investment underscores...

Rigel Pharmaceuticals published final results from the Phase 1/2 ARROW study of pralsetinib (Gavreto) for RET fusion-positive metastatic NSCLC in the Journal of Clinical Oncology, adding 42 months...

The FDA has twice opted not to approve Replimune’s oncolytic immunotherapy RP1 for melanoma despite breakthrough therapy designation and fast-track expectations, according to the account provided....

Erasca’s shares fell sharply after the company disclosed a fatal adverse event connected to ERAS-0015, its oral pan-RAS molecular glue in early trials. The disclosure accompanied preliminary...

Researchers have identified CD44+ monocytes as key drivers of inflammation in bronchopulmonary dysplasia (BPD) in very premature infants, tying a specific immune cell phenotype to the...

A new method combining shock-scattering micro-histotripsy with fine needle aspiration (FNA) aims to improve how much cellular material is retrieved for downstream biomarker profiling and...

Scientists report progress toward organisms with fewer amino-acid building blocks by partially eliminating isoleucine usage in Escherichia coli ribosome proteins, with the research published in...

A study identifies cGAS–STING hyperactivation as a mechanism that may help explain the elevated risk of liver inflammation seen in individuals with Down syndrome. By linking innate immune sensing...

A study in the British Journal of Cancer assesses the cost-effectiveness of integrating AI into the UK breast cancer screening program alongside traditional mammography. The analysis evaluates the...

Researchers report that African swine fever virus (ASFV) uses an MGF505-1R protein to degrade the host factor p300, helping the virus manipulate cellular machinery to support replication and...

The FDA rejected RP1, an engineered oncolytic herpesvirus therapy by Replimune Group, despite earlier “breakthrough therapy” designation tied to promising melanoma trial results. The agency has...

Biotech capital markets remain active, with April bringing the biggest month for IPO proceeds in more than five years. Four new biotech companies priced upsized offerings, raising $1.5 billion,...